Publications

BibTex format

@article{Sigfrid:2020:10.1101/2020.08.26.20180950,
author = {Sigfrid, L and Cevik, M and Jesudason, E and Lim, WS and Rello, J and Amuasi, JH and Bozza, F and Palmieri, C and Munblit, D and Holter, JC and Kildal, AB and Russell, CD and Ho, A and Turtle, L and Drake, TM and Beltrame, A and Hann, K and Bangura, IR and Fowler, R and Lakoh, S and Berry, C and Lowe, DJ and McPeake, J and Hashmi, M and Dyrhol-Riise, AM and Donohue, C and Plotkin, DR and Hardwick, H and Elkheir, N and Lone, N and Docherty, AB and Harrison, EM and Baille, KJ and Carson, G and Semple, MG and Scott, JT},
doi = {10.1101/2020.08.26.20180950},
title = {What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? - A harmonised, global longitudinal observational study},
url = {http://dx.doi.org/10.1101/2020.08.26.20180950},
year = {2020}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - <jats:p>IntroductionVery little is known about possible clinical sequelae that may persist after resolution of the acute Coronavirus Disease 2019 (COVID-19). A recent longitudinal cohort from Italy including 143 patients recovered after hospitalisation with COVID-19 reported that 87% had at least one ongoing symptom at 60 day follow-up. Early indications suggest that patients with COVID-19 may need even more psychological support than typical ICU patients. The assessment of risk factors for longer term consequences requires a longitudinal study linked to data on pre-existing conditions and care received during the acute phase of illness. Methods and analysisThis is an international open-access prospective, observational multi-site study. It will enrol patients following a diagnosis of COVID-19. Tier 1 is developed for following up patients day 28 post-discharge, additionally at 3 to 6 months intervals. This module can be used to identify sub-sets of patients experiencing specific symptomatology or syndromes for further follow up. A Tier 2 module will be developed for in-clinic, in-depth follow up. The primary aim is to characterise physical consequences in patients post-COVID-19. Secondary aim includes estimating the frequency of and risk factors for post-COVID- 19 medical sequalae, psychosocial consequences and post-COVID-19 mortality. A subset of patients will have sampling to characterize longer term antibody, innate and cell-mediated immune responses to SARS-CoV-2. Ethics and disseminationThis collaborative, open-access study aims to characterize the frequency of and risk factors for long-term consequences and characterise the immune response over time in patients following a diagnosis of COVID-19 and facilitate standardized and longitudinal data collection globally. The outcomes of this study will inform strategies to prevent long term consequences; inform clinical management, direct rehabilitation, and inform public health management to reduce overall mo
AU  - Sigfrid,L
AU  - Cevik,M
AU  - Jesudason,E
AU  - Lim,WS
AU  - Rello,J
AU  - Amuasi,JH
AU  - Bozza,F
AU  - Palmieri,C
AU  - Munblit,D
AU  - Holter,JC
AU  - Kildal,AB
AU  - Russell,CD
AU  - Ho,A
AU  - Turtle,L
AU  - Drake,TM
AU  - Beltrame,A
AU  - Hann,K
AU  - Bangura,IR
AU  - Fowler,R
AU  - Lakoh,S
AU  - Berry,C
AU  - Lowe,DJ
AU  - McPeake,J
AU  - Hashmi,M
AU  - Dyrhol-Riise,AM
AU  - Donohue,C
AU  - Plotkin,DR
AU  - Hardwick,H
AU  - Elkheir,N
AU  - Lone,N
AU  - Docherty,AB
AU  - Harrison,EM
AU  - Baille,KJ
AU  - Carson,G
AU  - Semple,MG
AU  - Scott,JT
DO  - 10.1101/2020.08.26.20180950
PY  - 2020///
TI  - What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? - A harmonised, global longitudinal observational study
UR  - http://dx.doi.org/10.1101/2020.08.26.20180950
ER  -

Download

DR. DANIEL MUNBLIT

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)